In a surprising turn of events and just weeks after upgrading its FY 15 guidance, Coloplast announced a guidance cut, trimming its growth expectations to 7% organic and 12% reported growth (vs. the previous 8-9% organic growth and 13-14% reported). Management cited the reasons as weakness in its two core markets – the UK and the US (with a larger impact from the UK). While the UK market continued to be challenged by issues in its Charter Healthcare business, the US growth has been weigh
18 Jun 2015
Coloplast hits a speedbump; downgrades guidance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Coloplast hits a speedbump; downgrades guidance
Coloplast A/S Class B (COLO:WBO) | 0 0 1.7% | Mkt Cap: 103,237m
- Published:
18 Jun 2015 -
Author:
Jyoti Prakash -
Pages:
3
In a surprising turn of events and just weeks after upgrading its FY 15 guidance, Coloplast announced a guidance cut, trimming its growth expectations to 7% organic and 12% reported growth (vs. the previous 8-9% organic growth and 13-14% reported). Management cited the reasons as weakness in its two core markets – the UK and the US (with a larger impact from the UK). While the UK market continued to be challenged by issues in its Charter Healthcare business, the US growth has been weigh